

In Gyu Hwang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5965959/publications.pdf>

Version: 2024-02-01

46
papers

611
citations

623734

14
h-index

642732

23
g-index

47
all docs

47
docs citations

47
times ranked

1210
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase II study of chemotherapy in combination with telomerase peptide vaccine (GV1001) as second-line treatment in patients with metastatic colorectal cancer. <i>Journal of Cancer</i> , 2022, 13, 1363-1369.	2.5	4
2	The first report of K-Umbrella Gastric Cancer Study: An open label, multi-center, randomized, biomarker-integrated trial for second-line treatment of advanced gastric cancer (AGC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4001-4001.	1.6	5
3	Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study. <i>Cancers</i> , 2021, 13, 331.	3.7	4
4	Clinical characteristics and survival of colorectal cancer patients in Korea stratified by age. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 985-991.	1.7	4
5	Rapid Progression of Coronary Atherosclerosis in Patients Taking an Oral Antitumor, Multikinase Receptor Inhibitor. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010705.	3.9	1
6	Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12. <i>Cancer Research and Treatment</i> , 2021, 53, 671-677.	3.0	14
7	Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3). <i>European Journal of Cancer</i> , 2021, 157, 21-30.	2.8	18
8	Gastric Mixed Adenoneuroendocrine Carcinoma with Revised Diagnosis after Retrospective Pathologic Review. <i>The Korean Journal of Helicobacter and Upper Gastrointestinal Research</i> , 2021, 21, 343-348.	0.4	1
9	Polypharmacy, Inappropriate Medication Use, and Drug Interactions in Older Korean Patients with Cancer Receiving First-Line Palliative Chemotherapy. <i>Oncologist</i> , 2020, 25, e502-e511.	3.7	32
10	Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3359-3369.	2.5	12
11	Prognostic Value of CD200R1 mRNA Expression in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2020, 12, 1777.	3.7	9
12	A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01). <i>Oncologist</i> , 2019, 24, 18-e24.	3.7	25
13	Assessment of spatial tumor heterogeneity using CT growth patterns estimated by tumor tracking on 3D CT volumetry of multiple pulmonary metastatic nodules. <i>PLoS ONE</i> , 2019, 14, e0220550.	2.5	3
14	The effects of BRCA1 expression on the chemosensitivity of gastric cancer cells to platinum agents. <i>Oncology Letters</i> , 2019, 17, 5023-5029.	1.8	3
15	Serum biomarkers for predicting overall survival and early mortality in older patients with metastatic solid tumors. <i>Journal of Geriatric Oncology</i> , 2019, 10, 749-756.	1.0	13
16	Sedation for terminally ill cancer patients. <i>Medicine (United States)</i> , 2019, 98, e14278.	1.0	12
17	ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4001-4001.	1.6	53
18	Expression of DNA Damage Response Markers in Early-Onset or Familial Gastric Cancers. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 1369-1376.	1.2	8

#	ARTICLE	IF	CITATIONS
19	Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma. <i>Cancer Research and Treatment</i> , 2019, 51, 300-312.	3.0	48
20	Prospective Validation of The Korean Cancer Study Group Geriatric Score (KG)-7, a Novel Geriatric Screening Tool, in Older Patients with Advanced Cancer Undergoing First-line Palliative Chemotherapy. <i>Cancer Research and Treatment</i> , 2019, 51, 1249-1256.	3.0	5
21	A Randomized Phase 2 Trial of Consolidation Chemotherapy After Preoperative Chemoradiation Therapy Versus Chemoradiation Therapy Alone for Locally Advanced Rectal Cancer: KCSG CO 14-03. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 889-899.	0.8	44
22	Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean Cancer Study Group (KCSG) multicentre prospective study. <i>British Journal of Cancer</i> , 2018, 118, 1169-1175.	6.4	25
23	Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study. <i>Cancer Communications</i> , 2018, 38, 1-8.	9.2	23
24	Results from the safety interim analysis of the Adjuvant chemoRadioTherapy In Stomach Tumors 2 (ARTIST 2) randomized, multi-center clinical trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16029-e16029.	1.6	1
25	Additional chemotherapy with 5-FU plus leucovorin between preoperative chemoradiotherapy and surgery improved treatment outcomes in patients with locally advanced rectal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15682-e15682.	1.6	0
26	Olanzapine and palonosetron without dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: A proof-of-concept trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, e22204-e22204.	1.6	0
27	The role of adjuvant therapy after R0 resection for patients with intrahepatic and perihilar cholangiocarcinomas. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 99-106.	2.3	18
28	Antiemetic Corticosteroid Rotation from Dexamethasone to Methylprednisolone to Prevent Dexamethasone-Induced Hiccup in Cancer Patients Treated with Chemotherapy: A Randomized, Single-Blind, Crossover Phase III Trial. <i>Oncologist</i> , 2017, 22, 1354-1361.	3.7	24
29	The Relationship between Physical Activity Intensity and Mental Health Status in Patients with Breast Cancer. <i>Journal of Korean Medical Science</i> , 2017, 32, 1345.	2.5	11
30	Association between timing and duration of adjuvant chemotherapy and survival for colorectal cancer in korea, 2011-2014: A nationwide study based on the database of quality assessment and the health insurance.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3605-3605.	1.6	3
31	Predicting cumulative incidence of chemotherapy toxicity in older patients with cancer: Korean Cancer Study Group prospective cohort study (KCSG) PC 13-09.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21539-e21539.	1.6	1
32	A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology. <i>Cancer Research and Treatment</i> , 2016, 48, 553-560.	3.0	19
33	Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 979-985.	2.3	30
34	A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 76-81.	1.9	12
35	Is There a Role for Adjuvant Therapy in R0 Resected Gallbladder Cancer?: A Propensity Score-Matched Analysis. <i>Cancer Research and Treatment</i> , 2016, 48, 1274-1285.	3.0	14
36	Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 757-762.	2.3	9

#	ARTICLE	IF	CITATIONS
37	Long-Term Intermittent Palliative Sedation for Refractory Symptoms at the End of Life in Two Cancer Patients. <i>Journal of Palliative Medicine</i> , 2015, 18, 807-810.	1.1	16
38	Occurrence of colonic liposarcoma after retroperitoneal liposarcoma. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 125.	1.7	5
39	Clinical features of metastatic renal cell carcinoma patients with intrinsic resistance to sunitinib: A Korean multicenter study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 462-462.	1.6	0
40	Placebo-controlled, double-blinded multi-center phase III trial of XELIRI/FOLFIRI plus simvastatin in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3576-3576.	1.6	3
41	Simvastatin plus capecitabine+ cisplatin versus placebo plus capecitabine+ cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study. <i>European Journal of Cancer</i> , 2014, 50, 2822-2830.	2.8	79
42	A retrospective, multicenter analysis of the clinicopathologic features of extra-gastrointestinal stromal tumor (EGIST).. <i>Journal of Clinical Oncology</i> , 2014, 32, 36-36.	1.6	0
43	Natural history of untreated patients who had metastatic biliary tract cancer (BTC) with good performance status (PS).. <i>Journal of Clinical Oncology</i> , 2014, 32, e15106-e15106.	1.6	0
44	A phase II trial of weekly docetaxel for second-line treatment of urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15613-e15613.	1.6	0
45	Relapsed Marginal Zone B-Cell Lymphoma: Clinical Features and Treatment Outcome.. <i>Blood</i> , 2009, 114, 5017-5017.	1.4	0
46	Treatment Outcome and Quality of Life in Non-Hodgkin's Lymphoma of Intestine: a Multicenter Study of the Consortium for Improving Survival of Lymphoma (CISL).. <i>Blood</i> , 2009, 114, 4992-4992.	1.4	0